$HUM

Is HealthStream (HSTM) a Better Healthcare Bet Than Humana (HUM) Right Now?

Humana (HUM) and HealthStream (HSTM) partnered to expand caregiver training. Humana reported Q2 2026 adjusted EPS of $7.61, lowering FY GAAP EPS guidance to $6.52. HealthStream saw Q2 revenue rise 12.5% to $83.7M, with net income up 23.8%. Humana faces regulatory pressures, while HealthStream benefits from strong margins and a debt-free balance sheet.

Original reporting
Published Sep 9, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Is HealthStream (HSTM) a Better Healthcare Bet Than Humana (HUM) Right Now? — source image
Decision brief

The 30-second read

$HUMBearishMed
01

Why it matters

Humana's guidance cut may trigger a sell‑off, while HealthStream's record results could attract buying interest.

02

Market read

Earnings releases for two publicly traded healthcare companies provide fresh data for traders to adjust positions.

03

What to watch

Humana's Medicaid partnership with HealthStream may create longer‑term synergies not reflected in the short‑term earnings miss.

Relevance 8/10Novelty 8/10Timing: post‑earnings release

Background

The article compares Q2 2026 earnings and outlook for Humana (a large insurer) and HealthStream (a health‑tech SaaS provider).

Company-level read

Ticker impact

$HUMBearishMedium confidence
Context

Humana reported Q2 2026 GAAP EPS of $5.73, adjusted EPS $7.61 and lowered FY GAAP EPS guidance to at least $6.52.

Expected impact

Potential short-term downside as investors reassess margin outlook.

Evidence & confidence

Guidance cut and high benefit ratio signal earnings pressure.

$HSTMBullishMedium confidence
Context

HealthStream posted Q2 2026 revenue of $83.7 M, operating income $8.3 M and net income $6.7 M, beating prior expectations.

Expected impact

Likely upside as investors reward growth and leverage improvement.

Evidence & confidence

Record revenue growth and margin expansion indicate momentum.

Market effects

Both companies highlight divergent trends in healthcare services vs. health‑tech software.

U.S. healthcare sector may see mixed reactions as insurers and SaaS providers diverge.

Limited to U.S. markets; no immediate global macro impact.

Counterpoint

HealthStream's small‑cap size could expose it to customer concentration risk despite strong earnings.

Key entities

  • Humana Inc.

    U.S. health insurance provider.

  • HealthStream, Inc.

    Provider of workforce training software for healthcare.

Related articles

$PGNYMedAI 8/10

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

$UNHHighAI 8/10

Health Insurer Stocks Are Soaring As Companies Get A Handle On Costs

UnitedHealth Group reported $5B in Q2 net income, with a declining medical care ratio. Shares of UnitedHealth, CVS Health, Centene, and Humana have risen significantly. Centene and Humana reported strong earnings, while Humana plans to exit some markets in 2027. Oscar Health entered new markets and saw its stock triple in six months.

$CNCMedAI 8/10

CNC, UNH, CVS, HUM Stocks Slip After-Hours — Trump Administration Reportedly Seeks To Scrap Subsidies On Certain Medicare Plans

Shares of Centene (CNC), UnitedHealth (UNH), CVS (CVS), and Humana (HUM) fell after-hours Tuesday after a report that the Trump administration plans to end a $3.6B federal subsidy for Medicare Part D plans post-2026. The subsidy helps keep premiums low for 25M enrollees. The loss of support could pressure margins and enrollment for insurers offering stand-alone Part D plans, though some beneficiaries may shift to Medicare Advantage plans.

Med

Glenmark USA Agrees to USD 15.28 Mn Settlement With Humana Over Generic Drug Antitrust Claims

Glenmark Pharmaceuticals said its U.S. subsidiary, Glenmark USA, agreed to settle with Humana Inc. for $15.28 million, including interest, to resolve antitrust and consumer protection claims over alleged generic drug price-fixing and market allocation. Glenmark USA denies all allegations. The company said the amount is already provided for in its financials and expects no significant financial impact.

Med

Glenmark’s U.S. unit settles Humana antitrust case for $15.3 mln

Glenmark Pharmaceuticals’ U.S. unit said, in an exchange filing, it reached a settlement with Humana to resolve antitrust litigation tied to consolidated generic-drug price-fixing claims in the Eastern District of Pennsylvania. The settlement totals $15.28 million plus interest, paid in two installments. Glenmark denied the allegations and said the amount was already booked in its financial statements.

MedAI 8/10

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

Glenmark Pharmaceuticals Ltd said its US unit, Glenmark Pharmaceuticals Inc., agreed to pay Humana Inc. $15.28 million to settle antitrust litigation over alleged price-fixing and market allocation in generic drugs. Glenmark said it denies all allegations and the settlement is not an admission of liability. The payment is in two installments and already provided for in its financials.